98%
921
2 minutes
20
Background: Metabolic syndrome, a cluster of illnesses including insulin resistance, hyperlipidemia, hypertension, and central obesity, is affecting roughly a quarter of the world population. Dysregulation of iron homeostasis may be associated with insulin resistance, leading to metabolic syndrome. Uric acid is an antioxidant currently studied in relation to several metabolic disorders. It may also be interlinked with iron metabolism. Yet, data regarding the interplay between serum iron, ferritin, and uric acid in metabolic syndrome are scarce. Hence, this study aimed to identify any alteration of serum iron, ferritin, and uric acid levels in metabolic syndrome patients of Eastern India and to explore any inter-relationship between these parameters. Methodology: A cross-sectional observational study including 103 patients suffering from metabolic syndrome and 107 age- and sex-matched healthy individuals was conducted. Subjects were evaluated for serum iron, ferritin, and uric acid levels, besides the diagnostic parameters of metabolic syndrome.
Results: Metabolic syndrome cases had higher serum iron, ferritin, and uric acid levels as compared to the controls. Serum uric acid was positively correlated with both iron and ferritin.
Conclusion: Metabolic syndrome is associated with elevated serum levels of iron, ferritin, and uric acid. Iron overload, reflected in elevated serum ferritin, can cause oxidative stress and endothelial damage, thereby predisposing to metabolic and vascular complications. Uric acid, an antioxidant, can rise in an attempt to counter oxidative stress. Metabolic syndrome patients should be periodically assessed for iron profile and uric acid to design suitable treatment protocols for better management of disease progression and alleviation of complications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531647 | PMC |
http://dx.doi.org/10.7759/cureus.70803 | DOI Listing |
Kardiologiia
September 2025
Department of Cardiology, The Ninth Medical Center, Chinese PLA General Hospital.
Background Hyperuricemia (HUA) frequently coexists with coronary artery disease (CAD) and is linked to adverse cardiovascular outcomes. The long-term impact of urate-lowering therapy (ULT) on clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), in CAD patients after percutaneous coronary intervention (PCI) has not been determined. That was the aim of this study.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).
Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.
Nutr Metab Cardiovasc Dis
July 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315040, PR China. Electronic address:
Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.
Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.
J Clin Neurosci
September 2025
Azienda Sanitaria Provinciale Catania, Catania, Italy. Electronic address:
J Appl Lab Med
September 2025
Department of Pathology, UC San Diego Health, San Diego, CA, United States.
Background: While clinical laboratories routinely perform automated chemistry assays on approved specimens (e.g., plasma and serum), the FDA has not evaluated the validity of these assays for nonapproved specimens (e.
View Article and Find Full Text PDF